Use of Sodium Glucose Cotransporter 2 Inhibitors in the Hands of Cardiologists: With Great Power Comes Great Responsibility

Circulation

Volumn 134, Issue 24, 2016, Pages 1915-1917

  Cherney, David Z I ^a,c   Udell, Jacob A ^b,c,d  

^a TORONTO GENERAL HOSPITAL   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

cardiovascular diseases; diabetes mellitus; heart failure; kidney; prevention and control; sodium glucose transporter 2

Indexed keywords

ANTIHYPERTENSIVE AGENT; HEMOGLOBIN A1C; LOOP DIURETIC AGENT; SACUBITRIL; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; THIAZIDE DIURETIC AGENT; VALSARTAN; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; EMPAGLIFLOZIN; GLUCOSIDE; SLC5A2 PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 2;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORONARY ARTERY ATHEROSCLEROSIS; GENITAL TRACT INFECTION; GLUCOSURIA; HEART PROTECTION; HIGH RISK PATIENT; HUMAN; MYCOSIS; NATRIURESIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PLASMA VOLUME; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; URINARY TRACT INFECTION; UROGENITAL TRACT INFECTION; WEIGHT REDUCTION; ANTAGONISTS AND INHIBITORS; CARDIOLOGIST; CLINICAL DECISION MAKING; COMORBIDITY; HEART FAILURE; METABOLISM; MORTALITY; PATIENT SELECTION; RISK FACTOR; TREATMENT OUTCOME;

BENZHYDRYL COMPOUNDS; CARDIOLOGISTS; CLINICAL DECISION-MAKING; COMORBIDITY; DIABETES MELLITUS, TYPE 2; GLUCOSIDES; HEART FAILURE; HUMANS; HYPOGLYCEMIC AGENTS; PATIENT SELECTION; RISK FACTORS; SODIUM-GLUCOSE TRANSPORTER 2; TREATMENT OUTCOME;

EID: 85005950549     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.116.024764     Document Type: Review

References (5)

1. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117-2128. doi: 10.1056/NEJMoa1504720.
2. Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, Redelmeier DA. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 2004;351:543-551. doi: 10.1056/NEJMoa040135.
3. Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation. 2016;134:752-772. doi: 10.1161/CIRCULATIONAHA.116.021887.
4. Harper W, Clement M, Goldenberg R, Hanna A, Main A, Retnakaran R, Sherifali D, Woo V, Yale JF, Cheng AY. Policies, guidelines and consensus statements: pharmacologic management of type 2 diabetes-2015 interim update. Can J Diabetes. 2015;39:250-252.
5. Sairaku A, Nakano Y, Kihara Y. Increased urine output by ipragliflozin in a non-diabetic patient with a diuretic-resistant heart failure. Int J Cardiol. 2015;180:42-43. doi: 10.1016/j.ijcard.2014.11.138.